Life360 and Nativo will combine family and location insights with premium publisher reach to help brands connect with families across more channelsLife360 + NativoLife360 & Nativo combined logosSAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) — Life360 (Nasdaq: LIF; ASX: 360), the leading family connection and safety company, today announced that it has entered into a definitive agreement to acquire Nativo, a leading advertising technology company that helps brands create and distribute engaging, premium ad experiences across premium publisher sites. The transaction is valued at approximately $120 million in a combination of cash and stock, subject to customary closing conditions. The acquisition advances the Life360 advertising strategy by uniting its rich first-party family and location insights with Nativo’s broad...

Paris, France, Nov. 10, 2025 (GLOBE NEWSWIRE) — North Atlantic France SAS provides updates on the contemplated acquisition of a majority stake in Esso Société Anonyme Française SA Turkish antitrust clearance obtained; transaction remains subject to French direct foreign investment authorization and EU Foreign Subsidies clearance Transaction target closing date set for November 28, 2025 Esso S.A.F. shareholders approved extraordinary distribution of €60.21 per share Assuming a closing on November 28, 2025, final purchase price of €26.19 per Esso S.A.F. share for the acquisition of the ExxonMobil block of shares and €28.93 per Esso S.A.F. share in the context of the tender offer Esso S.A.F. to be renamed “North Atlantic Energies” upon completion of the transactionParis, FRANCE, November 10, 2025 – North Atlantic France SAS...

ANNOUNCEMENT APPROVAL OF THE REVISION OF THE VOLUNTARY SHARE EXCHANGE TENDER OFFER MADE BY EURONEXT N.V. (“OFFEROR” OR “EURONEXT”) FOR THE ORDINARY REGISTERED SHARES OF HELLENIC EXCHANGES-ATHENS STOCK EXCHANGE S.A. (“ATHEX”) TENDER OFFER REVISIONOn 7 November 2025, (the “Date of the Revision”), Euronext announced that in accordance with Article 21, paragraph 2 of Law 3461/2006 (the “Law”), it has submitted to the Hellenic Capital Market Commission (the “HCMC”) a request to revise the voluntary tender offer (the “Tender Offer”) that the Offeror had submitted on 30 July 2025 (the “Date of the Tender Offer”) aiming to acquire all ordinary registered shares, each having a nominal value of €0.42 (each, a “ATHEX Share”) issued by ATHEX, which Euronext and any “persons acting in concert” (as defined in article 2(e) of the Law) with Euronext,...

Copenhagen, Denmark: Global towage and marine solutions provider, Svitzer Group A/S (Svitzer), has acquired a 66.6% stake in leading Norwegian towage and marine service company, Buksér og Berging AS, subject to final regulatory approvals. Svitzer’s investment represents a partnership opportunity for both companies, with a view to leverage extensive shared knowledge and experience of the global towage, offshore, adjacent maritime service and marine solution markets. Buksér og Berging AS is a leading supplier of marine services within port and terminals, towage, offshore work and complex marine operations in Norway. Svitzer is a leading, global towage and marine services provider with more than 450 vessels globally. There is no integration activities related to the transaction for either company and Buksér og Berging will continue to operate...

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — Epiq announced today the sale of its Global Business Transformation Solutions (Epiq GBTS) division to K2 Services, a leading managed services provider. Epiq is a technology and services leader, taking on large-scale and complex tasks for corporations, law firms, and the courts by integrating people, process, technology, and data intelligence to streamline legal, compliance, and settlement workflows. “At Epiq, we made a commitment to our clients to never leave them behind when it comes to technology and its application,” said David Dobson, CEO of Epiq. “The sale of Epiq GBTS is a strategic shift as we continue to focus on innovation, expanding our technology portfolio, and delivering even greater impact to our clients across the legal ecosystem.” Epiq is the most advanced alternative legal...

CHICAGO, Nov. 10, 2025 (GLOBE NEWSWIRE) — K2 Services, a leading provider of comprehensive managed services, announced today its acquisition of Epiq Global Business Transformation Solutions (Epiq GBTS) and Forrest Solutions. These three strategic organizations will come together to form a powerful new entity poised to drive transformative impact for their professional services and legal clients. These acquisitions were supported by Renovus Capital Partners, a private equity firm with over $2 billion in assets across its sector-focused funds. With the acquisitions of Epiq GBTS, an Epiq Global division, and Forrest Solutions, K2 is redefining how businesses mobilize — establishing itself as the operational backbone that enables organizations to focus on their core competencies. It will be uniquely positioned to deliver comprehensive,...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree JTC PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree IQE PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

On 5 May 2025, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 20 of 2 May 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 120 million during the period 5 May to 31 December 2025. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount    Accumulated until 31 October 2025 168,600 599.12 101,012,339    Monday, 3 November 2025 1,300 595.23 773,799    Tuesday, 4 November 2025 1,300 584.77 760,201    Wednesday, 5 November 2025 1,400 581.67 814,338    Thursday, 6 November 2025 1,400 579.00 810,600    Friday,...

Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative Neoplasms  Damora Therapeutics, the sixth company launched based on assets developed by Paragon Therapeutics, is advancing a portfolio of anti-mutant calreticulin (mutCALR) targeted therapies, led by DMR-001, a potentially best-in-class monoclonal antibody targeting mutCALR Combined company with complementary assets expected to have financial runway into 2029 to support multiple data milestones, including Phase 1 clinical proof-of-concept data for DMR-001 anticipated in 2027 BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) — Galecto, Inc. (“Galecto”) today announced the completion of the acquisition of Damora Therapeutics, Inc. (“Damora”),...